Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis Read more about Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Amgen Reports Fourth Quarter And Full Year 2019 Financial Results Read more about Amgen Reports Fourth Quarter And Full Year 2019 Financial Results
Amgen Announces Webcast Of 2019 Fourth Quarter And Full Year Financial Results Read more about Amgen Announces Webcast Of 2019 Fourth Quarter And Full Year Financial Results
Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences Read more about Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer Read more about Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
Amgen To Present At The 38th Annual J.P. Morgan Healthcare Conference Read more about Amgen To Present At The 38th Annual J.P. Morgan Healthcare Conference
Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference Read more about Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China Read more about Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration Read more about Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture Read more about European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
